Jubilant Life Sciences Ltd.'s generic version of Aptiom, a seizure treatment, infringes six patents, a U.S. subsidiary of Sumitomo Dainippon Pharma Co. said in a new lawsuit.
Sunovion Pharmaceuticals Inc., based in Massachusetts, and Portuguese drugmaker Bial-Portela & Ca. SA allege Jubilant’s generic infringes six patents covering Aptiom (eslicarbazepine acetate). The tablet is approved to treat partial-onset seizures in patients 4 years old and older. The suit was filed March 1 in the U.S. District Court for the District of Delaware.
Sunovion and Bial have been aggressively defending Aptiom from generic competition lately. The companies also filed an infringement suit ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.